Keratin 17 testing in pancreatic cancer needle aspiration biopsies predicts survival.
immunohistochemistry
keratin 17
needle aspiration biopsies
pancreatic ductal adenocarcinoma
prognostic biomarker
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
11
03
2021
received:
18
12
2020
accepted:
31
03
2021
pubmed:
3
6
2021
medline:
15
4
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
Although pancreatic ductal adenocarcinoma (PDAC) has one of the lowest 5-year survival rates of all cancers, differences in survival exist between patients with clinically identical characteristics. The authors previously demonstrated that keratin 17 (K17) expression in PDAC, measured by RNA sequencing or immunohistochemistry (IHC), is an independent negative prognostic biomarker. Only 20% of cases are candidates for surgical resection, but most patients are diagnosed by needle aspiration biopsy (NAB). The aims of this study were to determine whether there was a correlation in K17 scores detected in matched NABs and surgical resection tissue sections and whether K17 IHC in NAB cell block specimens could be used as a negative prognostic biomarker in PDAC. K17 IHC was performed for a cohort of 70 patients who had matched NAB cell block and surgical resection samples to analyze the correlation of K17 expression levels. K17 IHC was also performed in cell blocks from discovery and validation cohorts. Kaplan-Meier and Cox proportional hazards regression models were analyzed to determine survival differences in cases with different levels of K17 IHC expression. K17 IHC expression correlated in matched NABs and resection tissues. NAB samples were classified as high for K17 when ≥80% of tumor cells showed strong (2+) staining. High-K17 cases, including stage-matched cases, had shorter survival. K17 has been identified as a robust and independent prognostic biomarker that stratifies clinical outcomes for cases that are diagnosed by NAB. Testing for K17 also has the potential to inform clinical decisions for optimization of chemotherapeutic interventions.
Sections du résumé
BACKGROUND
Although pancreatic ductal adenocarcinoma (PDAC) has one of the lowest 5-year survival rates of all cancers, differences in survival exist between patients with clinically identical characteristics. The authors previously demonstrated that keratin 17 (K17) expression in PDAC, measured by RNA sequencing or immunohistochemistry (IHC), is an independent negative prognostic biomarker. Only 20% of cases are candidates for surgical resection, but most patients are diagnosed by needle aspiration biopsy (NAB). The aims of this study were to determine whether there was a correlation in K17 scores detected in matched NABs and surgical resection tissue sections and whether K17 IHC in NAB cell block specimens could be used as a negative prognostic biomarker in PDAC.
METHODS
K17 IHC was performed for a cohort of 70 patients who had matched NAB cell block and surgical resection samples to analyze the correlation of K17 expression levels. K17 IHC was also performed in cell blocks from discovery and validation cohorts. Kaplan-Meier and Cox proportional hazards regression models were analyzed to determine survival differences in cases with different levels of K17 IHC expression.
RESULTS
K17 IHC expression correlated in matched NABs and resection tissues. NAB samples were classified as high for K17 when ≥80% of tumor cells showed strong (2+) staining. High-K17 cases, including stage-matched cases, had shorter survival.
CONCLUSIONS
K17 has been identified as a robust and independent prognostic biomarker that stratifies clinical outcomes for cases that are diagnosed by NAB. Testing for K17 also has the potential to inform clinical decisions for optimization of chemotherapeutic interventions.
Identifiants
pubmed: 34076963
doi: 10.1002/cncy.22438
pmc: PMC9014629
mid: NIHMS1797829
doi:
Substances chimiques
Biomarkers, Tumor
0
Keratin-17
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
865-873Subventions
Organisme : Hirshberg Foundation for Pancreatic Cancer Research
Organisme : National Science Foundation
ID : HRD-1311318
Organisme : National Pancreas Foundation
Organisme : NCI NIH HHS
ID : R00 CA226342
Pays : United States
Organisme : NCI NIH HHS
ID : K99-R00 CA226342-01
Pays : United States
Organisme : Pancreatic Cancer Action Network
ID : 18-65-SHRO
Pays : United States
Organisme : Damon Runyon Cancer Research Foundation
Pays : United States
Informations de copyright
© 2021 American Cancer Society.
Références
Ann Surg Oncol. 2017 Jul;24(7):2023-2030
pubmed: 28213792
Curr Mol Med. 2014 Mar;14(3):309-15
pubmed: 24345208
Pancreatology. 2018 Mar;18(2):176-183
pubmed: 29305088
Mod Pathol. 2014 Apr;27(4):621-30
pubmed: 24051697
Mod Pathol. 2019 May;32(5):717-724
pubmed: 30443013
Ann Oncol. 2019 Sep 1;30(9):1428-1436
pubmed: 31161208
Cytopathology. 2020 Mar;31(2):90-95
pubmed: 31808243
Int J Cancer. 2021 Feb 1;148(3):769-779
pubmed: 32895958
Hum Pathol. 2017 Apr;62:23-32
pubmed: 27816721
Endosc Ultrasound. 2017 Dec;6(Suppl 3):S76-S78
pubmed: 29387696
Hum Pathol. 2019 Dec;94:40-50
pubmed: 31655172
Cancers (Basel). 2018 Jan 20;10(1):
pubmed: 29361690
Sci Rep. 2019 Aug 2;9(1):11239
pubmed: 31375762
J Cytol. 2019 Oct-Dec;36(4):189-195
pubmed: 31741576
Cancer Res. 2015 Sep 1;75(17):3650-62
pubmed: 26109559
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Oncol. 2020 Aug;14(8):1800-1816
pubmed: 32533886
J Gastroenterol Hepatol. 2019 May;34(5):907-913
pubmed: 30422342
Pancreas. 2016 May-Jun;45(5):761-71
pubmed: 26784908